Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the feasibility of four weeks of
preoperative immunotherapy with Nivolumab, and Nivolumab plus Relatlimab in patients with
early stage or locally advanced non-small cell lung cancer eligible for curative resection.